1
|
Zhang J, Qiu X, Feng J, Liu Y. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas. Chin Neurosurg J 2024; 10:24. [PMID: 39049072 PMCID: PMC11267829 DOI: 10.1186/s41016-024-00375-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2024] [Accepted: 07/15/2024] [Indexed: 07/27/2024] Open
Abstract
BACKGROUND High-grade gliomas (HGGs) have a rapid relapse and short survival. Studies have identified many clinical characteristics and biomarkers associated with progression-free survival (PFS) and over-survival (OS). However, there has not yet a comprehensive study on survival after the first progression (SAP). METHODS From CGGA and TCGA, 319 and 308 HGGs were confirmed as the first progression. The data on clinical characteristics and biomarkers were analyzed in accordance with OS, PFS, and SAP. RESULTS Analysis of 319 patients from CGGA, significant predictors of improved OS/PFS/SAP were WHO grade, MGMT promoter methylation, and Ki-67 expression in univariate analysis. Further multivariate analysis showed MGMT promoter methylation and Ki-67 expression were independent predictors. However, an analysis of 308 patients from TCGA found MGMT promoter methylation is the only prognostic marker. A longer SAP was observed in patients with methylated MGMT promoter after standard chemoradiotherapy. In our data, HGGs could be divided into low, intermediate, and high-risk groups for SAP by MGMT methylation and Ki-67 expression. CONCLUSIONS Patients with MGMT promoter methylation have a prolonger SAP after standard chemoradiotherapy. HGGs could be divided into low, intermediate, and high-risk groups for SAP according to MGMT status and Ki-67 expression.
Collapse
Affiliation(s)
- Jing Zhang
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China
| | - Xiaoguang Qiu
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China
| | - Jin Feng
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China
| | - Yanwei Liu
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
| |
Collapse
|
2
|
Cheng L, Yuan M, Li S, Lian Z, Chen J, Lin W, Zhang J, Zhong S. Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients. ANNALS OF TRANSLATIONAL MEDICINE 2021; 9:925. [PMID: 34350240 PMCID: PMC8263857 DOI: 10.21037/atm-21-1986] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Accepted: 05/06/2021] [Indexed: 12/11/2022]
Abstract
Background Brain glioblastoma multiforme (GBM) is the most common primary malignant intracranial tumor. The prognosis of this disease is extremely poor. While the introduction of β-interferon (IFN-β) regimen in the treatment of gliomas has significantly improved the outcome of patients; The mechanism by which IFN-β induces increased TMZ sensitivity has not been described. Therefore, the main objective of the study was to elucidate the molecular mechanisms responsible for the beneficial effect of IFNβ in GBM. Methods Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA) GBM and GSE83300 dataset from the Gene Expression Omnibus. Univariate Cox regression analysis and lasso Cox regression model established a novel 4-gene IFN-β signature (peroxiredoxin 1, Sec61 subunit beta, X-ray repair cross-complementing 5, and Bcl-2-like protein 2) for GBM prognosis prediction. Further, GBM samples (n=50) and normal brain tissues (n=50) were then used for real-time polymerase chain reaction experiments. Gene set enrichment analysis (GSEA) was performed to further understand the underlying molecular mechanisms. Pearson correlation was applied to calculate the correlation between the long non-coding RNAs (lncRNAs) and IFN-β-associated genes. An lncRNA with a correlation coefficient |R2|>0.3 and P<0.05 was considered to be an IFN-β-associated lncRNA. Results Patients in the high-risk group had significantly poorer survival than patients in the low-risk group. The signature was found to be an independent prognostic factor for GBM survival. Furthermore, GSEA revealed several significantly enriched pathways, which might help explain the underlying mechanisms. Our study identified a novel robust 4-gene IFN-β signature for GBM prognosis prediction. The signature might contain potential biomarkers for metabolic therapy and treatment response prediction for GBM patients. Conclusions In the present study, we established a novel IFN-β-associated gene signature to predict the overall survival of GBM patients, which may help in clinical decision making for individual treatment.
Collapse
Affiliation(s)
- Lijing Cheng
- Department of Neurology, The First Affiliated Hospital of Dali University, Dali University, Dali, China.,Clinical Medical School, Dali University, Dali, China
| | - Meiling Yuan
- Department of Neurology, The First Affiliated Hospital of Dali University, Dali University, Dali, China.,Clinical Medical School, Dali University, Dali, China
| | - Shu Li
- Department of Neurology, Jinshan Hospital, Benxi Jinshan Affiliated Hospital of Dalian Medical University, Benxi, China
| | - Zhiying Lian
- Second Clinical Medical College, Southern Medical University, Guangzhou, China
| | - Junjing Chen
- Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, China
| | - Weibiao Lin
- Department of Neurosurgery, Zhongshan City People's Hospital, Zhongshan, China
| | - Jianbo Zhang
- Department of Neurosurgery, Zhongshan City People's Hospital, Zhongshan, China
| | - Shupeng Zhong
- Department of Oncology, Zhongshan City People's Hospital, Zhongshan, China
| |
Collapse
|
3
|
Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal. Biomed Pharmacother 2019; 118:109261. [DOI: 10.1016/j.biopha.2019.109261] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Revised: 07/11/2019] [Accepted: 07/24/2019] [Indexed: 01/01/2023] Open
|
4
|
Chakraborty S, Ghosh Z. A systemic insight into astrocytoma biology across different grades. J Cell Physiol 2018; 234:4243-4255. [DOI: 10.1002/jcp.27193] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 07/17/2018] [Indexed: 01/05/2023]
Affiliation(s)
| | - Zhumur Ghosh
- Bioinformatics Centre, Bose Institute Kolkata India
| |
Collapse
|
5
|
Liu C, Wang L, Qiu H, Dong Q, Feng Y, Li D, Li C, Fan C. Combined Strategy of Radioactive 125I Seeds and Salinomycin for Enhanced Glioma Chemo-radiotherapy: Evidences for ROS-Mediated Apoptosis and Signaling Crosstalk. Neurochem Res 2018; 43:1317-1327. [DOI: 10.1007/s11064-018-2547-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 05/05/2018] [Accepted: 05/11/2018] [Indexed: 01/29/2023]
|
6
|
Bi YL, Mi PY, Zhao SJ, Pan HM, Li HJ, Liu F, Shao LR, Zhang HF, Zhang P, Jiang SL. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Int J Mol Med 2017; 39:1255-1261. [PMID: 28358414 PMCID: PMC5403467 DOI: 10.3892/ijmm.2017.2940] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 03/27/2017] [Indexed: 12/22/2022] Open
Abstract
Tumor angiogenesis plays a crucial role in tumor growth, progression and metastasis, and suppression of tumor angiogenesis has been considered as a promising anticancer strategy. Salinomycin (SAL), an antibiotic, displays novel anticancer potential against several human cancer cells in vitro and in vivo. However, little information concerning its anti-angiogenic properties is available. Therefore, the anti‑angiogenic effect of SAL and the underlying mechanism in human glioma were evaluated in the present study. The results indicated that SAL treatment significantly inhibited human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion and capillary-like tube formation. Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs. Pretreatment of cells with a PI3K inhibitor (LY294002) and FAK inhibitor (PF562271) markedly enhanced SAL-induced inhibition of HUVEC proliferation and migration, respectively. Moreover, U251 human glioma xenograft growth was also effectively blocked by SAL treatment in vivo via inhibition of angiogenesis involving FAK and AKT depho-sphorylation. Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.
Collapse
Affiliation(s)
- Yan-Ling Bi
- Department of Cardiology, Taian Central Hospital, Taian, Shandong 271000, P.R. China
| | - Pei-Yan Mi
- Department of Cardiology, Taian Central Hospital, Taian, Shandong 271000, P.R. China
| | - Shi-Jun Zhao
- Key Laboratory of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Heng-Ming Pan
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
| | - Hui-Juan Li
- Department of Cardiology, Taian Central Hospital, Taian, Shandong 271000, P.R. China
| | - Fei Liu
- Department of Breast Surgery, Taian Central Hospital, Taian, Shandong 271000, P.R. China
| | - Lu-Rong Shao
- Key Laboratory of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Hui-Fang Zhang
- Key Laboratory of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Pu Zhang
- Department of Cardiology, Taian Central Hospital, Taian, Shandong 271000, P.R. China
| | - Shi-Liang Jiang
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
| |
Collapse
|
7
|
Xu WZ, Li F, Xu ZK, Chen X, Sun B, Cao JW, Liu YG. Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma. Onco Targets Ther 2017; 10:725-733. [PMID: 28223828 PMCID: PMC5308575 DOI: 10.2147/ott.s127441] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Objective Impaired immunonutritional status has disadvantageous effects on outcomes for cancer patients. Preoperative albumin-to-globulin ratio (AGR) and the prognostic nutrition index (PNI) have been used as prognostic factors in various cancers. We aimed to evaluate the clinical significance of the AGR and PNI in glioblastoma. Materials and methods This retrospective analysis involved 166 patients. Demographic, clinical, and laboratory data were collected. AGR and the PNI were calculated as AGR = albumin/(total serum protein − albumin) and PNI = albumin (g/L) + 5 × total lymphocyte count (109/L). Overall survival (OS) was estimated by Kaplan–Meier analysis. Receiver-operating characteristic analysis was used to assess the predictive ability of AGR and the PNI. Cox proportional-hazard models estimating hazard ratios (HRs) and 95% confidence intervals (CIs) were used for univariable and multivariable survival analyses. Results The cutoff values of AGR and PNI were 1.75 and 48. OS was enhanced, with high AGR (>1.75) and the PNI (>48) (P<0.001 for both). Areas under the receiver-operating characteristic curve for AGR and the PNI were 0.68 and 0.631 for 1-year survival and 0.651 and 0.656 for 2-year survival (P<0.05 for all), respectively. On multivariable analyses, both AGR and the PNI were independent predictors of OS (AGR, HR 0.785, 95% CI 0.357–0.979 [P=0.04]; PNI, HR 0.757, 95% CI 0.378–0.985 [P=0.039]). On subgroup analysis, AGR and the PNI were significant prognostic factors for OS in patients with adjuvant therapy (AGR P<0.001; PNI P=0.001). Conclusion Preoperative AGR and the PNI may be easy-to-perform and inexpensive indices for predicting OS with glioblastoma. AGR and the PNI could also help in developing good adjuvant-therapy schedules.
Collapse
Affiliation(s)
- Wen-Zhe Xu
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| | - Feng Li
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| | - Zhen-Kuan Xu
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| | - Xuan Chen
- Department of Radiation Oncology, Qilu Hospital, Shandong University, Jinan, People's Republic of China
| | - Bin Sun
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| | - Jing-Wei Cao
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| | - Yu-Guang Liu
- Department of Neurosurgery, Qilu Hospital; Brain Science Research Institute
| |
Collapse
|
8
|
Mayrhofer M, Gourain V, Reischl M, Affaticati P, Jenett A, Joly JS, Benelli M, Demichelis F, Poliani PL, Sieger D, Mione M. A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth. Dis Model Mech 2017; 10:15-28. [PMID: 27935819 PMCID: PMC5278524 DOI: 10.1242/dmm.026500] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 11/11/2016] [Indexed: 12/12/2022] Open
Abstract
Somatic mutations activating MAPK and PI3K signalling play a pivotal role in both tumours and brain developmental disorders. We developed a zebrafish model of brain tumours based on somatic expression of oncogenes that activate MAPK and PI3K signalling in neural progenitor cells and found that HRASV12 was the most effective in inducing both heterotopia and invasive tumours. Tumours, but not heterotopias, require persistent activation of phospho (p)-ERK and express a gene signature similar to the mesenchymal glioblastoma subtype, with a strong YAP component. Application of an eight-gene signature to human brain tumours establishes that YAP activation distinguishes between mesenchymal glioblastoma and low grade glioma in a wide The Cancer Genome Atlas (TCGA) sample set including gliomas and glioblastomas (GBMs). This suggests that the activation of YAP might be an important event in brain tumour development, promoting malignant versus benign brain lesions. Indeed, co-expression of dominant-active YAP (YAPS5A) and HRASV12 abolishes the development of heterotopias and leads to the sole development of aggressive tumours. Thus, we have developed a model proving that neurodevelopmental disorders and brain tumours might originate from the same activation of oncogenes through somatic mutations, and established that YAP activation is a hallmark of malignant brain tumours.
Collapse
Affiliation(s)
- Marie Mayrhofer
- Institute for Toxicology and Genetics, Hermann von Helmholtz Platz 1, Eggenstein-Leopoldshafen 76344, Germany
| | - Victor Gourain
- Institute for Toxicology and Genetics, Hermann von Helmholtz Platz 1, Eggenstein-Leopoldshafen 76344, Germany
| | - Markus Reischl
- Institute for Applied Informatics at Karlsruhe Institute of Technology, Hermann von Helmholtz Platz 1, Eggenstein-Leopoldshafen 76344, Germany
| | - Pierre Affaticati
- Tefor Core Facility, Paris-Saclay Institute of Neuroscience, CNRS, Université Paris-Saclay, Gif-sur-Ivette 91190, France
| | - Arnim Jenett
- Tefor Core Facility, Paris-Saclay Institute of Neuroscience, CNRS, Université Paris-Saclay, Gif-sur-Ivette 91190, France
| | - Jean-Stephane Joly
- Tefor Core Facility, Paris-Saclay Institute of Neuroscience, CNRS, Université Paris-Saclay, Gif-sur-Ivette 91190, France
| | - Matteo Benelli
- Centre for Integrative Biology, University of Trento, Via Sommarive 9, Trento 38123, Italy
| | - Francesca Demichelis
- Centre for Integrative Biology, University of Trento, Via Sommarive 9, Trento 38123, Italy
| | - Pietro Luigi Poliani
- Department of Molecular and Translational Medicine, Pathology Unit, University of Brescia School of Medicine, Spedali Civili Brescia, Brescia 25123, Italy
| | - Dirk Sieger
- Centre for Neuroregeneration, The University of Edinburgh, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Marina Mione
- Institute for Toxicology and Genetics, Hermann von Helmholtz Platz 1, Eggenstein-Leopoldshafen 76344, Germany
- Centre for Integrative Biology, University of Trento, Via Sommarive 9, Trento 38123, Italy
| |
Collapse
|